Chipscreen Biosciences
CompanyChina
Chipscreen Biosciences develops 2 assets, the furthest in phase 3 (Chiglitazar/Metformin in type 2 diabetes). Mostly small molecule acting on AMPK signalling, Insulin/IGF-1 signalling and lipid and ceramide metabolism; based in China.
- 2
- Assets
- Furthest stage
- Phase 3
- 9
- Trials
- 1
- Signal
Pipeline
2Dual-action combination therapy improving insulin sensitivity and glucose homeostasis via pan-PPAR activation and hepatic gluconeogenesis inhibition.
Phase 3, Small molecule, AMPK signalling, Insulin/IGF-1 signalling, type 2 diabetes
Stage not known, Small molecule
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms7
- Trials11
- Signals1
- Similar companies6